Can mirtazapine and Wellbutrin (bupropion) be combined?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Combining Mirtazapine and Wellbutrin (Bupropion)

Yes, mirtazapine and Wellbutrin (bupropion) can be safely combined and may provide complementary benefits for patients with depression, particularly those with specific symptom profiles or who have had inadequate response to monotherapy.

Pharmacological Rationale for Combination

Mirtazapine and bupropion work through different mechanisms:

  • Mirtazapine: Acts as an α2-adrenergic antagonist and 5-HT2/5-HT3 receptor antagonist, increasing norepinephrine and serotonin neurotransmission 1
  • Bupropion (Wellbutrin): Uniquely targets norepinephrine and dopamine neurotransmitters with no appreciable activity on serotonin 2

This combination provides complementary neurotransmitter effects:

  • Mirtazapine enhances serotonergic and noradrenergic activity
  • Bupropion enhances dopaminergic and noradrenergic activity

Clinical Benefits of Combination

The combination offers several potential advantages:

  • Complementary symptom management:

    • Mirtazapine helps with sleep, anxiety, and appetite 1
    • Bupropion helps with energy, motivation, and concentration 1
  • Counterbalancing side effects:

    • Bupropion's activating properties may offset mirtazapine's sedation
    • Mirtazapine's appetite-stimulating effects may balance bupropion's appetite suppression
  • Enhanced efficacy: Research suggests antidepressant combinations from treatment initiation may double remission rates compared to monotherapy 3

Dosing Recommendations

  • Mirtazapine: Start at 7.5-15 mg at bedtime, can be titrated up to 30 mg at bedtime 1
  • Bupropion: Start at 37.5 mg every morning, increase by 37.5 mg every 3 days to target dose of 150 mg twice daily 1
  • Maximum doses: Mirtazapine 45 mg/day; Bupropion 400 mg/day (SR) or 450 mg/day (IR) 1

Safety Considerations

  1. No significant drug interaction concerns: Unlike many other antidepressant combinations, there is no explicit warning against combining mirtazapine and bupropion 1

  2. Seizure risk: Bupropion lowers seizure threshold, so:

    • Avoid in patients with seizure disorders
    • Keep bupropion dose within recommended limits
    • Use caution in patients with factors that predispose to seizures 1
  3. Monitoring recommendations:

    • Blood pressure and heart rate (both medications can affect cardiovascular parameters)
    • Weight changes (opposing effects may balance each other)
    • Sleep quality and daytime energy levels
    • Follow-up every few weeks initially, then monthly once stabilized 1

Special Populations and Considerations

  • Elderly patients: Both medications are considered appropriate options for older adults, but start at lower doses and titrate more slowly 1

  • Patients with insomnia: Administer mirtazapine at bedtime to leverage its sedating properties 1

  • Patients with anxiety: The combination may be particularly helpful for patients with comorbid anxiety and depression 2

  • Smoking cessation: Bupropion is FDA-approved for smoking cessation, making this combination potentially beneficial for depressed patients who also smoke 2

Potential Pitfalls and Caveats

  • Timing of administration: To minimize insomnia risk, bupropion should be given in the morning and no later than 3 PM for a second dose 1

  • Agitation risk: Avoid initiating this combination in agitated patients as bupropion can be activating 1

  • Weight effects: Monitor weight as mirtazapine tends to increase appetite while bupropion may suppress it 2

  • Discontinuation: If discontinuation is needed, taper gradually rather than stopping abruptly to minimize withdrawal symptoms 4

This combination represents a rational pharmacological approach that targets multiple neurotransmitter systems and may be particularly useful for patients with depression who have not responded adequately to monotherapy or who have specific symptom profiles that would benefit from the complementary effects of these medications.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Other Antidepressants.

Handbook of experimental pharmacology, 2019

Guideline

Weight Management with Contrave (Naltrexone/Bupropion)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.